Investors focused on the Medical space have likely heard of Gilead Sciences (GILD), but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Gilead Sciences is a member of our Medical group, which includes 844 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. GILD is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for GILD's full-year earnings has moved 5.91% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, GILD has returned 5.68% so far this year. Meanwhile, stocks in the Medical group have gained about 5.14% on average. This means that Gilead Sciences is outperforming the sector as a whole this year.
Looking more specifically, GILD belongs to the Medical - Biomedical and Genetics industry, a group that includes 352 individual stocks and currently sits at #77 in the Zacks Industry Rank. On average, this group has gained an average of 1.51% so far this year, meaning that GILD is performing better in terms of year-to-date returns.
GILD will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research